主要先進国におけるHIV治療動向（～2019）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 9
2.1 Disease Introduction 9
2.2 Route of HIV Transmission 10
2.3 Etiology 10
2.4 Classification of HIV-1 Subtypes 11
2.5 Pathophysiology 11
2.5.1 HIV-1 Replication Cycle 12
2.5.2 Mechanism of CD4 T-Cell Death 13
2.5.3 Latent Infection and Viral Persistence 14
2.6 Symptoms 14
2.7 Diagnosis 15
2.7.1 HIV Antibody Assay 15
2.7.2 Rapid HIV Antibody Test 16
2.7.3 Western Blot 16
2.7.4 HIV p24 Antigen Test 16
2.7.5 Antigen-Antibody Immunoassay 16
2.7.6 Polymerase Chain Reaction Test 16
2.7.7 HIV Home-Testing Kit 17
2.8 Disease Staging 17
2.8.1 WHO Clinical Staging 17
2.8.2 Centers for Disease Control and Prevention Classification System 19
2.8.3 Immunological Classification 19
2.9 Co-morbidities and Complications 20
2.10 Epidemiology 21
2.11 Treatment Options 22
2.11.1 Nucleoside/Nucleotide Reverse Transcriptase Inhibitor 23
2.11.2 Non-Nucleoside Reverse Transcriptase Inhibitor 23
2.11.3 Entry Inhibitor 23
2.11.4 Integrase Inhibitor 23
2.11.5 HIV-1 Protease Inhibitor 24
2.11.6 Pharmacokinetic Enhancer 24
2.12 Treatment Algorithm 24
3 Marketed Products 29
3.1 Therapeutic Landscape 31
3.1.1 Multi-class Combinations 31
3.1.2 Nucleotide Reverse Transcriptase Inhibitors 35
3.1.3 Non-Nucleoside Reverse Transcriptase Inhibitor 44
3.1.4 HIV Protease Inhibitor 48
3.1.5 Integrase Inhibitor 55
3.1.6 Entry Inhibitor 57
3.2 Comparative Efficacy and Safety 60
3.2.1 Multi-class Combination 62
3.2.2 Nucleotide Reverse Transcriptase Inhibitor 62
3.2.3 Non-Nucleotide Reverse Transcriptase Inhibitor 63
3.2.4 HIV Protease Inhibitor 63
3.2.5 Integrase Inhibitor 64
3.2.6 Entry Inhibitor 64
3.3 Unmet Need 65
4 Pipeline for HIV 67
4.1 Overall Pipeline 67
4.2 Mechanism of Action in HIV Pipeline 70
4.3 Clinical Trials 72
4.3.1 Failure Rate of Developmental Pipeline 72
4.3.2 Clinical Trial Sizes 76
4.3.3 Clinical Trial Duration 80
4.3.4 Summary of Clinical Trial and Risk Analysis 84
4.4 Promising Candidates in Pipeline 85
4.4.1 572-Trii (dolutegravir + abacavir sulfate + lamivudine) – Shionogi-ViiV Healthcare 85
4.4.2 Atazanavir sulfate + cobicistat – Bristol-Myers Squibb, Gilead 86
4.4.3 Elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide – Gilead 88
4.4.4 Apricitabine – Avexa 90
4.4.5 Remune (IR-103) – Immune Response BioPharma 91
4.4.6 Censavudine – Bristol-Myers Squibb 93
4.4.7 Elvucitabine – Achillion 94
4.4.8 Cenicriviroc – Tobira Therapeutics 95
4.5 Heat Map and Competitor Matrix for HIV Pipeline Products 97
5 Market Forecast to 2019 103
5.1 Geographical Markets 103
5.1.1 Global Market 106
5.1.2 North America 107
5.1.3 Top Five Countries in Europe 112
5.1.4 Japan 117
5.2 Drivers and Barriers 119
5.2.1 Drivers 119
5.2.2 Barriers 120
6 Deals and Strategic Consolidations 122
6.1 Major Co-development Deals 122
6.1.1 DFH Pharma Enters Agreement with Hetero Drugs 124
6.1.2 GlaxoSmithKline Enters Agreement with Concert Pharmaceuticals 125
6.1.3 GenVec Enters Agreement with SAIC-Frederick 125
6.2 Major Licensing Deals 125
6.2.1 Merck Enters Agreement with Chimerix 128
6.2.2 Bristol-Myers Squibb Enters Agreement with Gilead 128
6.2.3 Japan Tobacco Enters Agreement with Gilead 129
6.2.4 Gilead Enters Agreement with Tibotec 129
6.2.5 Benitec Enters Agreement with Calimmune 129
6.2.6 Bristol-Myers Squibb Enters Agreement with Oncolys BioPharma 129
7 Appendix 130
7.1 All Pipeline Products, by Phase 130
7.1.1 Discovery 130
7.1.2 Preclinical 137
7.1.3 Phase I 142
7.1.4 Phase II 145
7.1.5 Phase III and Pre-registration 148
7.2 Tabular Forecast Data 149
7.2.1 Global 149
7.2.2 US 149
7.2.3 Canada 150
7.2.4 UK 150
7.2.5 France 150
7.2.6 Germany 151
7.2.7 Italy 151
7.2.8 Spain 152
7.2.9 Japan 152
7.3 Sources 153
7.4 Market Definition 164
7.5 Abbreviations 164
7.6 Research Methodology 167
7.6.1 Coverage 167
7.6.2 Secondary Research 167
7.7 Therapeutic Landscape 167
7.8 Epidemiology-Based Forecasting 168
7.9 Market Size by Geography 169
7.10 Geographical Landscape 169
7.11 Pipeline Analysis 170
7.12 Competitive Landscape 170
7.12.1 Expert Panel Validation 170
7.13 Contact Us 170
7.14 Disclaimer 170